DRKS00020290
Recruiting
Not Applicable
RADprecise - Personalized radiotherapy: incorporating cellular response to irradiation in personalized treatment planning to minimize radiation toxicity - RADprecise
Deutsches Krebsforschungszentrum (DKFZ) / German Cancer Research Center0 sites1,050 target enrollmentJanuary 3, 2020
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- C50
- Sponsor
- Deutsches Krebsforschungszentrum (DKFZ) / German Cancer Research Center
- Enrollment
- 1050
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult breast or prostate cancer patients who received radiotherapy and have participated in the REQUITE study in Germany, Italy, Spain, UK and who are alive at re\-contact
- •\- Willingness and ability to comply with at least one scheduled visit
- •\- The capacity to understand the patient information sheet and the ability to provide written informed consent
Exclusion Criteria
- •\- Re\-irradiation of the region of initial radiotherapy (including contralateral breast)
- •\- Any breast surgery after initial RT, mastectomy patients (including contralateral breast)
- •\- Mental disability or patient otherwise unable to give informed consent and/or complete patient questionnaires
- •\- Known HIV infection, hepatitis B or hepatitis C not eligible for sample collection
Outcomes
Primary Outcomes
Not specified
Similar Trials
Suspended
Not Applicable
Radiobiological characterisation and therapy monitoring of oligo- compared to polymetastatic breast cancerC50Malignant neoplasm of breastDRKS00031591Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Hamburg-Eppendorf50
Not yet recruiting
Not Applicable
Towards Response guided ADAptive Radiotherapy for organ preserving treatment of intermediate risk rectal cancer: a phase I dose finding trialrectal cancerrectal carcinoma100179901001799110017998NL-OMON51912niversitair Medisch Centrum Utrecht45
Recruiting
Not Applicable
Towards Response guided ADAptive Radiotherapy for organ preserving treatment of intermediate risk rectal cancer: a phase I dose finding trialrectal cancerNL-OMON22916MC Utrecht45
Not yet recruiting
Not Applicable
Radiationtreatment planning for Cervical and Head andNeck cancer using machineHealth Condition 1: C539- Malignant neoplasm of cervix uteri, unspecifiedHealth Condition 2: C14- Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynxCTRI/2023/05/053119Medical Research Council University College London
Active, not recruiting
Phase 2
MR-Guided Adaptive Stereotactic Body Radiotherapy (SBRT) of Primary Tumor for Pain Control in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) – a Randomized, Controlled Clinical StudyC25Malignant neoplasm of pancreasDRKS00025801MU Klinikum10